Journal article
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Abstract
BACKGROUND: Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear.
METHODS: In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of …
Authors
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF
Journal
The New England Journal of Medicine, Vol. 378, No. 7, pp. 615–624
Publisher
Massachusetts Medical Society
Publication Date
February 15, 2018
DOI
10.1056/nejmoa1711948
ISSN
0028-4793